WHO Drug Information, Vol. 15, No. 2, 2001
`
`Proposed INN: List 85
`
`International Nonproprietary Namesfor
`Pharmaceutical Substances (INN)
`
`
`
`Notice is hereby given that, in accordance with article 3 ofihe Procedure for the Selection of RecommendedInternational
`Nonproprietary Names for Pharmaceutical Substarces, the names givenin thelist on the following pages are under
`consideration by the World Health Organization as Proposed International Nonproprietary Names. Theinclusion ofa name
`inthelists of Proposed international Nonproprietary Names does not imply any recommendation of the use ofthe substance
`in medicine or pharmacy.
`
`- Lists of Proposed (1—73) and Recommended(1-35) International Nonproprietary Names can be found in Cumulative List
`No. 9, 1996. The s:atements indicating action anduse are based largely on information supplied by the manufacturer. This
`information is merely meantto provide an indication ofthe potential use of new substancesatthe time they are accorded
`Proposed International Nonproprietary Names, WHOis notin a position eitherto uphold these statements orto comment
`on the efficacy of the action claimed. Because cftheir provisional nature, these descriptorswill neither be revised nor
`included inthe Cumu ative Lists of INNs.
`
`Dénominations communes internationales
`des Substances pharmaceutiques (DCI)
`liestnotifié que, conformémentaux dispositions del'article 3 de la Procédure a suivre en vue du choixde Dénominations
`communesinternationales recommandées pour les Substances pharmaceutiquesles dénominations ci-dessous sont
`mises alétude par |'Organisation mondiale de la Santé en tant que dénominations communesinternationales proposées.
`‘inclusion d'une dénomination dansleslistes de DC! proposées n'implique aucune recommandation envue de!utilisation
`de la substance correspondante en médecine ou en pharmacie.
`
`Ontrouvera d'autreslistes de Dénominations communesinternationales propasées(1-73) et recommandées (1-35) dans
`la Liste récapjtulative No. 9, 1996. Les mentions indiquant les propriétéset les indications des substances sont fondées
`surles renseignements communiquéspar le fabricant. Elles ne visent qu’é donner une idée del'utilisation potentielle des
`nouvelles substances au moment otelles sont ‘objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer
`ces déclarationsni de faire de commentairessur l'efficacité du mode d'action ainsi décrit. En raison de leur caractére
`provisoire, ces informations ne figurerontpas dans leslistes récapitulatives de DCI.
`
`Denominaciones Comunes Internacionales
`para las Sustancias Farmacéuticas (DCI)
`De conformidad con lo que dispone el parrafo 3 del “Procedimiento de Seleccién de Denominaciones Comunes
`Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunicapor el presente anuncio que las
`denominacionesdetalladas en las paginas siguientes estan sometidas a estudio por la Organizacion Mundialde La Salud
`como Denominaciones ComunesInternacionales Propuestas.La inclusién de una denominacion en las listas delas DCI
`Propuestas no supone recomendacién alguna en favordel empleo de {a sustancia respectivaen medicinao en farmacia.
`
`Laslistas de Denominaciores ComunesInternacionales Propuestas (1-73) y Recomendadas (1-35) se encuentran
`reunidas en Cumulative List No. 9, 1996. Las indicaciones sobre accién y uso que aparecen se basan principalmente
`en la informaciérfacilitada por los fabricantes. Esta informacién tiene por objeto dar una idea tnicamente de las
`posibilidades de aplicacién de las nuevas sustanciasalas que se asigna una DCI Propuesta, LaOMS noesta facultada
`para respaldaresasindicacicnesni para formular comentarios sobrela eficacia de la accion que seatribuye al producto.
`Debido a su caracterprovisional, esos datos descriptivos na debenincluirse enlaslistas recapitulativas de DCI.
`
`95
`
`OSI 2018
`OSI 2018
`APOTEX V. OSI
`APOTEX V. OSI
`IPR2016-01284
`
`IPR2016-01284
`
`

`

`Proposed INN:List 85
`
`WHO Drug Information, Vol. 15, No. 2, 2001
`
`ProposedInternational Nonproprietary Names: List 85
`Commentson, or formal objectionsto, the proposed names maybe forwarded by any person to the INN Programmeof
`the World Health Organization within four monthsofthe date oftheir publication in WHO Drug information,i.e., for List
`85 Proposed[NN notlater than 31 January 2002.
`
`Dénominations communesinternationales proposées: Liste 85
`Des observations ou des objections formeliesa l'égard des denominations proposées peuvent&tre adresséespartoute
`personne au Programme des Dénominations communesinternationales de I'Organisation mondiale dela Santé dans un
`délai de quatre mois 4 compterde la date de leur publication dans WHO Drug information,c'est a dire pourla Liste 85
`de DCI Proposées le 31 janvier 2002 au plus tard.
`
`Denominaciones ComunesInternacionales Propuestas: Lista 84
`Cualquierpersona puededirigir observacionesu objeciones respecto de las denominaciones propuestas,al Programa
`de Denominaciones ComunesInternacionales de la Organizacién Mundial de la Salud, en un plazo de cuatro meses,
`contados desdela fecha de su publicacién en WHO Drug information, es decir, para la Lista 85 de DCI Propuestas
`el 31 de enero de 2002 a mastardar.
`
`ProposedINN
`(Latin, English, French, Spanish}
`
`Chemical name or description: Action and use: Molecular formula
`Chemical Abstracts Service (CAS) registry number: Graphic formula
`
`DCI Proposée
`
`DC! Propuesta
`
`acidum gadocoleticum
`gadocoletic acid
`
`acide gadocolétique
`
`acido gadocolético
`
`Nom chimique ou description: Propriétés et indications: Formule brute
`Numéro dansle registre du CAS: Formule développée
`
`Nombre quimico o descripcién: Accién y uso: Férmula empirica
`Numero de registro del CAS: Férmula desarrofiada
`
`trihydrogen [3f-[[(4S)-4-[bis[2-[bis[(carboxy-« O)methyllamino-«NJethyljamino-
`«N]-4-(carboxy-«O)butanoyllamino]-12a-hydroxy-5p-cholan-24-oato(6-)}=
`gadolinate(3-)
`diagnostic agent
`
`trihnydrogéno[3B-{[(4 S)-4-[bis[2-[bis[(carboxy-xO)méthylJamino-cVJéthyljamino-
`«xN]-4-(carboxy-«O}butanoylJamino]-12a-hydroxy-5B-cholan-24-oato(6-)]=
`gadolinate(3-)
`produit & usage diagnostique
`
`trihidrogeno[3B-[[(4 S)-4-[bis[2-[bis[(carboxi-x O)metil]amino-xNjetillamino-«Nj-
`4-(carboxi-« O)butanoillamino]-120-hidroxi-5p-colan-24-oato(6-)jgadolinato(3-)
`agente de diagnéstico
`
`Cc,4H,,GdN,0,,
`
`
`
`96
`
`

`

`WHODrug information, Vol. 15, No. 2, 2001
`
`Proposed INN: List 85
`
`afeletecanum
`afeletecan
`
`afélétécan
`
`afeletecan
`
`alfimeprasum
`alfimeprase
`
`alfiméprase
`
`alfimeprasa
`
`camptothecin, ester with N-[[p-[(3-O-methyl-a-.-fucopyranosyljoxyjphenyl)=
`thiocarbamoyl}-t-histidyl-_-valine
`antineoplastic
`
`(28)-2-[[(2S)-3-(1 H-imidazol-4-y}}-2-[[[[4-[(3-O-meéthyl-6-désoxy-4-.-
`galactopyranosyljoxy]phényljamino]thiocarbonyl]amino]propanoyljamino]-
`3-méthylbutaneate de (4S)-4-éthyl-3, 14-dioxo-3,4,12,14-46trahydro-
`1H-pyrano[3’,4':6,7]indolizino[ 1 ,2-b]quinoléin-4-yle
`antinéoplasique
`
`éster de la camptotecina con N-[[p-[(3-O-metil-a-_-fucopiranosiljoxilfenil]=
`tiocarbamoil]-_-histidil-_-valina
`antineoplasico
`
`C,H,.N,O,.S
`
`215604-75-4
`
`
`
`{3-L-serine]fibrolase-(3-203)-peptide (fibrolase < fibrinolytic enzyme isolated
`from Agkistroden contrix contix venom)
`antithrombotic
`
`[3-:-sérine}fibrolase-{3-2C3)-peptide (fibrolase : enzymefibrinolytique extraite
`de venin d'Agkistrodon contrix contrix)
`antithrombotigue
`
`(3-.-serinalfibrolasa-(3-203)-péptido (fibrolasa : enzime fibrinolitica extraida
`de veneno de Agkistrodon contrix contnx)
`antithrombético
`
`Coase NyeSOsg)8.
`
`259074-76-5
`
`SPPORYVE
`INELYRPLAT
`
`LAYVGGMCQL
`AIDFDGDTVG
`NWRETOLLRR
`
`
`KHSTGVIQDH
`‘
`GANSCVMAAN LSDQPSKLFS DCSKKDYOTF|LTVNNPCCIL
`
`
`NKE
`
`97
`
`PRYNGDSDKI
`SNODLITVTS
`
`ROQWVHOIVNT
`VSHDTLASFG
`
`MANSLGHNLG MNHDGN2CHE
`
`

`

`Proposed INN: List 85
`
`WHODrug Information, Vol. 15, No. 2, 2001
`
`alicaforsenum
`alicaforsen
`
`alicaforsen
`
`alicaforseno
`
`alilusemum
`alilusem
`
`alilusem
`
`alilusem
`
`2'-deoxy-(F)-P-thioguanylyi-(3'5')-2'-deaxy-(R)-P-thiacytidyly!-(3'>5'}-
`2'-deoxy-(R)-P-thiocytidylyl-(3' 5')-2'-deoxy-(R)-P-thiocytidylyl-(3'-95')-
`2'-deoxy-(R)-P-thioadenylyl-(3'-5’)-2'-deoxy-( R)-P-thioadenylyl-(3'>5')-
`2'-deoxy-(R)-P-thioguanylyl-(3'->5')-2'-deoxy-(R)-P-thiocytidyly|-(3'3.5'}-
`(R}-P-thiothymidylyl-(3'35')-2'-deoxy-(R)-P-thioguanylyl-(3'>5')-2'-deoxy-
`(R)-P-thioguanylyl-(3'35'}-2'-deoxy-(R)-P-thiocytidylyl-(3'> 5')-2'-deoxy-
`(R)-P-thioadenyly|-(3'5')-(R)-P-thiothymidylyl-(3'5')-2'-deaxy-(R)-P-
`thiocytidylyl-(3'-»5'}-2’-deoxy-(R)-P-thiocytidylyl-(3’5’)-2'-deoxy-(R)-F-
`thioguanylyl-(3'->5')-(R)-P-thiothymidylyl-(3". >5'}-2'-deoxy-(R)-P-thiocytidylyl-
`(3'35'}-2'-deoxyadenosine noradecasodium salt
`antisense phosphorotioale oligonucleotide
`
`2'-désoxy-(R)-P-thioguanyly!-(3’5')-2'-désaxy-(R)-P-thiocytidylyl-(3'5")-
`2'-désoxy-(R)-P-thiocytidylyl-(3'-»5’)-2'-désoxy-(R)-P-thiocytidylyl-(3'>5')-
`2'-désoxy-(R)-P-thioadénylyl-(3'5')-2'-désoxy-(R)-P-thioadénylyl-(3'35')-
`2'-désoxy-(R)-P-thioguanylyl-(3'>5')-2'-désoxy-(R)-P-thiocytidylyl-(3'35')-
`(R)-P-thiothymidylyl-(3'->5')-2'-désoxy-(R)-P-thioguanyly|-(3'-55')-2'-désoxy-
`(R)-P-thioguanylyl-(3'-»5')-2’-désoxy-(R)-P-thiocytidylyl-(3'»5’)-2'-désoxy-
`(R)-P-thioadénylyi-(3'35')-(R)-P-thiothymidylyl-(3'5')-2'-désaxy-(R)-P-
`thiocytidylyl-(3'->5')-2’-désoxy-(R)-P-thiocytidylyl-(3'~»5')-2’-désoxy-(R)-P-
`thioguanytyl-(3'5')-(R)-P-thiothymidylyl-(3'5')-2'-désoxy-(R)-P-
`thiocytidylyl-(3’-+5')-2"-désoxyadénosine nonadécasodique
`inhibiteur de la synthése de fa protéine d’adhésion ICAM-1
`
`2'-desoxi-(R)-P-tioguanilil-(3' 5')-2'-desoxi-(R)-P-tiocitidilil-(3'5')}-2’-desoxi-
`(R)-P-tiocitidilil-(3'+ 5")-2'-desoxi-(R)-P-tiocitidilil-(3'3§')-2'-des oxi-(R)-P-
`tioadenilil-(3'-»5')-2'-desoxi-(R)-P-ticadenilil-(3'-+5')-2'-desoxi-(R)-P-
`tioguanilil-(3'-»5-2'-desoxi-(R)-P-tiocitidili-(3'->5')-(R)-P-tiotimidilil-(3>$')-
`2'-desoxi-(R)-P-tioguanilil-(3'5')-2'-desoxi-(R)-P-tioguanilil-(3'>5')-
`2'-desoxi-(R)-P-tiocitidilil-(3'5')-2'-desoxi-(R)-P-tioadenilil-(3'5’)-(R)-P-
`tiotimidilil-(3'->5')-2'-desoxi-(R)-P-tiocitidilll-(3’+ 5')-2"-desaxi-(R)-P-tiocitidifil-
`(3'~5')-2"-desoxi-(R)-P-tioguanilil-(3'5')-(R)-P-tiatimidilil-(3'>5')-2'-desoxi-
`{R)-P-tiocitidilil-(3'5')-2'-desoxiadenosina nonadecasddica
`cadena complementaria {oligonuciedtido fosforotioato}
`
`CegHypeNagNjgQsePaeSig
`
`185229-68-9
`
`7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1H)-one (&)-O-
`sulfooxime
`diuretic
`
`(E)-O-sulfooxime de 7-chloro-1-(2-méthylbenzoyl)-2,3-dihydroquinoléin-
`4(1H)-one
`diurétique
`
`(E)-O-sulfooxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1)-ona
`diurético
`
`

`

`WHODrugInformation, Vol. 15, No. 2, 2004
`
`Proposed INN: List 85
`
`
`
`a 48
`C,,4,.CIN,O.S
`
`144506-11-6
`
`~S03H
`
`CK3 0
`
`(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yloxy]-3-methoxy-3,3-diphenylpropanoic
`acid
`endothelin receptor antagonist
`
`(+)-acide (2S)-2-[(4,6-diméthylpyrimidin-2-yi) oxyl-3-méthoxy-
`3,3-diphénylpropanoique
`antagonisie du récepteur de i'endothéiine
`
`(+)-acido (2S)-2-[(4,6-dimetilpirimidin-2-if)oxi)-3-metoxi-3,3-difenilpropanoico
`antagonista del receptor de endotelina
`
`C,H,NO,
`
`177036-94-1
`
`
`
`[(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1 .3-dioxeian-2-yl]methanol
`antiviral
`
`[(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)- 4 ,3-dioxo'an-2-yl]méthanol
`antiviral
`
`{(2R,4R)-4-(2,6-diamino-SH-purin-9-i:)-1 ,3-dioxolan-2-il]metanol
`antiviral
`
`C.H,,N,O.
`
`145514-04-1
`
`ambrisentanum
`ambrisentan
`
`ambrisentan
`
`ambrisentan
`
`amdoxovirum
`amdoxovir
`
`amdoxovir
`
`amdoxovir
`
`
`99
`
`

`

`Proposed INN: List 85
`
`WHODrug Information, Vol. 15, No. 2, 2001
`
`
`
`amelubantum
`amelubant
`
`amélubant
`
`amelubant
`
`amotosalenum
`amotosalen
`
`amotosaléne
`
`amotosaleno
`
`bimatoprostum
`bimatoprost
`
`bimatoprost
`
`bimatoprost
`
`100
`
`ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]Jphenoxyjmethy!Jbenzyt)=
`oxy]pheny!]{imine)methyl]carbamate
`leukotriene receptor antagonist
`
`{{4-[[3-[[4-[1-(4-hydroxyphényl)-1-méthyléthyl]phénoxy}méthyl]benzyljoxy]=
`phényl}imino)méthyljcarbamate d'éthyle
`antagoniste du récepteur des leucotriénes
`
`([4-[[3-[[4-[1-(4-hidroxifenil)-1-metileti}fenoxijmetil]Jbenciljoxijfenil](imino}metil}=
`carbamato de etilo
`antagonista del receptor de feucotrienos
`
`C..HN,O,
`
`3-[(2-aminoethoxy)methyi]-2,5,9-trimethy-7H-furo[3,2-g}[1]benzopyran-7-one
`photochemical therapy
`
`3-[(2-aminoéthoxy)méthyl]-2,5,9-triméthyl-7H-furo[3,2-g][1 ]benzopyran-7-one
`photochimiothérapie
`
`3-{(2-aminoetoxi)metil]-2,5,9-trimetil-74-furo[3,2-g][1 Joenzopiran-7-ona
`terapia fotoquimica
`
`C,,H,,NO,
`
`161262-29-9
`
`Q
`
`Han i
`
`HC
`
`©
`
`CH,
`
`CH,
`
`SS
`
`07
`
`So
`
`(Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-[(1£,3S)-3-hydroxy-5-phenyl-
`1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide
`antiglaucoma
`
`(Z)-7-[4R,2R,3R,5S)-3,5-dihydroxy-2-[(1£,3S)-3-hydroxy-5-phénylpent-
`1-ényl]cyclopenty!]-N-éthylhept-5-énamide
`antiglaucomateux
`
`(Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-[(1 £,3S)-3-hidroxi-5-fenilpent-
`f-eniljciclopentil]-N-etilhept-5-enamida
`antiglaucoma
`
`

`

`WHODrug Information, Vol. 15, No. 2, 2004
`
`Proposed INN: List 85
`
`CgH,NO,
`
`155206-00-1
`
`CH3
`
`5-methyl-2-(piperazin-1-yl}benzenesulfonic acid
`cardiac stimulant
`
`acide 5-méthy!-2-(pipérazin-1-ylbenzénesulfonique
`cardiotonique
`
`acido 5-metil-2-(piperazin-1-ilbencenosulfénico
`cardiotdnico
`
`C,H,NOS
`
`133804-44-1
`
`‘Sey 3HNOh
`
`4-[(1R,2R)-2-(5,6-dimethy!hex-1-ynyl)cyclopropyl}-1 H-imidazole
`histamine-H, receptor antagonist
`
`4-[(1R,2R)-2-(5,5-diméthyihex-1-ynyl) cyclopropyi]-1H-imidazoie
`antagoniste des récepteurs H, de histamine
`
`4-[(1R,2R)-2-(5,5-dimetilnex-1-inil}ciclopropil]-1H-imidazol
`antagonista de los receptores H, de fa histamina
`
`C,,HN,
`
`213027-19-1
`
`caldaretum
`caldaret
`
`caldaret
`
`caldaret
`
`cipralisantum
`cipralisant
`
`cipralisant
`
`cipralisant
`
`H
`
`8
`NA.
`ip
`
`eyv SyH:C CH
`
`SS
`
`
`101
`
`

`

`Proposed INN: List 85
`
`WHODrug Information, Vol. 15, No. 2, 2001
`
`
`
`dalbavancinum
`dalbavancin
`
`dalbavancine
`
`dalbavancina
`
`5,31-dichioro-38-de(methoxycarbonyl)-7-demethyl- 1 9-deoxy-56-O0-[2-deoxy-
`2-((10-methylundecanoyl)amino]-b-d-glucopyranuronosyl]-38-[[3-
`(dimethylamino)propyl]carbamoyl}-42-O-a-d-mannopyranosy|-15-N-
`methyl(ristomycin A aglicone)
`antibiotic
`
`acide 2-désoxy-1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dichloro-
`38-[[3-(diméthylamino)propyl]carbamoyl]-6,11,34,40,44-pentahydroxy-42-
`(a-d-mannopyranosyloxy)-15-(méthylamino)-2,16,36,50,51,59-hexaoxo-
`2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tétradécahydro-20,23:30,33-
`diéthéno-3, 18:35,48-bis(iminométhano)-1H, 15H-4,8:10, 14:25,28:43, 47-
`tétraméthéno-34H-[1,14,6,22]dioxadiazacyclooctacosino[4 ,5-
`m][10,2, 16]benzoxadiazacyclotétracosén-56-yl}-2-[(10-
`méthylundécanoy!jamino}-b-d-glucopyranuronique
`antibiotique
`
`acido 1-0-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dicloro-38-
`[[3-(dimetilamino)propiljcarbamoil]-6, 1 1,34,40,44-pentahidroxi-42-
`(a-b-manopiranosiloxi)-15-(metilamino)-2,16,36,50,51 ,59-hexaoxo-
`2,3,16,17,18,19,35,36,37,38, 48,49, 50,50a-tetradecahidro-20,23:30,33-
`dieteno-3,18:35,48-bis(iminometano)-1H, 15H-4,8:10,14:25,28:43,47-
`tetrameteno-34H-[1 ,14,6,22]dioxadiazaciclooctacosino[4,5-m][10,2,16]=
`benzoxadiazaciclotetracosen-56-il]-2-[(10-metilundecanoil}amino]-2-desoxi-
`§-o-glucopiranurénico
`antibistico
`
`CoHioCLNOng
`
`171500-79-1
`
`HO:
`
`
`
`
`102
`
`

`

`WHODrug Information, Vol. 15, No. 2, 2004
`
`Proposed INN: List 85
`
`darbepoetinum alfa
`darbepoetin alfa
`
`darbépoétine alfa
`
`darbepoetina alfa
`
`[39-L-asparagine, 32-1 -thronine,87-.-valine 88-L-asparagine,
`90-L-threcninejerythropofetin (human)
`antianaemis
`
`[30-t-asparacine,32-i-thréonine.87-_-valine,88-1-asparagine,
`90-.-thréoninelérythropoiétine humaine
`antianenique
`
`[30-L-asparagina,32--treonina,87-1-valina 88-1-asparagina,
`90-.-treoninaleritropoietina humana
`antianémico
`
`KC 1300" 8 2435
`Co AN pO
`reas
`
`209810-58-2
`
`APPRLICDSR VLERYLLEAK EAENITTGCN ETCSLNENIT
`
`SEAVLRGQAL
`VPDTKVNFYA WKRMEVGOQQA VEVWQGLALL
`LVNSSQVNET
`LOLHVDKAVS GLRSLTTLLR ALGAQKEAIS
`PPDASSAAPL
`RTITADTFRK LFRVYSNFLR GKLKLYTGEA
`CRTED
`
`
`
`drotrecoginum alfa
`drotrecogin alfa
`
`drotrécogine alfa
`
`drotrecogina alfa
`
`blood coagulation factor XIV (human)
`anticoagulant
`
`facteur XIV humain de coagulation sanguine
`anticoagulant
`
`factor XIV de coagulacién sanguinea (humano}
`anticoagulante
`
`103
`
`

`

`Proposed INN: List BS
`
`WHO Drug Information, Vol. 15, No, 2, 2001
`
`31SS)
`“S81
`B40"
`31
`GorpaParseNen Ono
`
`98530-76-8
`
`ICDFJJAKJI
`ANSFLJJLRH SSLURJCIGIJ
`FONVDDTLAF
`OOSSSTT
`
`WSKHVDGDOC LVLPLEHPCA SLCCGHGTCI BGIGSFSEDELT
`I af
`RSGWEGRFCQ REVSFLNCSL
`DNGGCTHYCL
`EEVGWRRCSC
`t
`7
`CGRPWKRMEK KRSHL
`
`APGYKLGDDI
`
`LOCHPAVKFP
`
`DTE
`
`DQEDOVDPRL|IDGKMTRRGD SPWOVVLLDS KKKLACGAVL
`
`ZHPSWVLTAA|HCMDESKKLL VRLGEYDLRR WEKWELDLDI
`KEVFVHPNYS KSTTDNDIAL
`LHLAQPATLS QTEVPICLED
`SGLAERELNQ AGQETLVTGW GYHSSREKEA
`KRNRTFVLNF
`IKIPVVPHNE
`CSEVMSNMVS
`ENMLCAGILG
`DRODACEGDS
`GGPMVASFHG
`TWFLVGLVSW GEGCGLLHNY GVYTKVSRYL
`
`DWIHGHIRDK BAPQKSWAP
`
`* glycosylation sites
`* sites de glycosylation
`* posiciones de glicosilacién
`
`HO
`
`CO2H
`H
`f
`
`HO2C
`
`COH
`
`H
`
`“
`
`B= —N
`Ho
`
`Je —N
`Hoo
`
`1-[(6Z,7E,20S8)-10,38-dihydroxy-9,10-secochola-5,7,10(19)-trien-
`24-oylJpiperidine
`antipsoriatic
`
`1-[(52,7E,20S)-1a,3f-dihydroxy-9,10-sécochola-5,7,10(19)-trién-
`24-oyl]pipéridine
`antipsoriasique
`
`1-[(52,7E,20S)-1a,38-dihidroxi-9,10-secocola-5,7,10{19)-trien-
`24-oil]piperidina
`antipsoriasico
`
`ecalcidenum
`ecalcidene
`
`écaicidéne
`
`ecalcideno
`
`104
`
`

`

`WHO Druginformation, Vol. 15, No. 2, 2001
`
`Proposed INN: Lisi 85
`
`CagHeNO,
`
`150337-94-3
`
`
`
`immunoglobulin G1, anti-(human antigen CD11a) (human-mouse monocional
`hu1124 +1-chain), disulfide with human-mouse monoclonal hu1124 light
`chain, dimer
`immunomodulator
`
`immunogiobuine G1, anti-(antigene CD11a humain) (chafne y1 de l'anticorps
`moclona! de souris humanisé hu1124),dimére du disulfure avec la chaine
`légére de l'anticorps mocional de souris hurmanisé hu1124
`immunomodulateur
`
`inmunoglobulina Gt, anti-(antigeno CD11a humano) (cadena y1 dei anticuerpe
`monoclonal humanizado de rat6n hu1124), dimero del disulfuroe con la
`cadena ligera del anticuerpo monoclonal humanizade de ratén hu1i24
`inmunomoduiador
`
`214745-43-4
`
`acetyl-i-tyrosyi-.-threonyl-.-seryl-i-leucyl-_-isoleucyl-L-histidyl-t-seryl-
`L-leucyl-L-isoleucyl-t-«-glutamyl-t-o-giutamyl-L-seryl-_-glutaminy:-
`L-asparaginyl--glutaminy!-L-glutaminy!-L-c-glutamyl--iysyl-L-asparaginyl-
`L-a-glutamyl---glutaminy!-.-c-giutamyl-_-leucyl-t-feucyl-1-o-glutamyl-t-leucyl-
`L-o-aspactyl-L-lysyl-i-tryptophyl-L-alanyl-.-seryl-L-leucyl-c-tryptophyl-
`L-asparaginyl-L-tryptophyl-_-phenylalaninamide
`antiviral
`
`acetyl-L-tyrosyl-L-thréonyl-t-séryl-.-leucyl-.-isoleucyl-_-histidy-t-séryl-
`L-leucyl-L-isoleucyl-L-a-giutamy!-t-a-glutamyl-_-séryl-_-glutaminy-
`L-asparaginyl-L-glutaminyl-t-glutaminyi-.-c:-glutamyl-t-lysyl-t-asparaginyl-
`L-e-glutamyl-1-glutaminy|-_-a-glutamy:_-leucyl-1-leucyl-t-a-glutamyl-t-leucyl-
`L-a-aspartyl-c-lysyl-.-tryptophyl-.-alanyl-t-séryl-+-leucyl-L-tryptophy!-
`L-asparaginyl-.-tryptophyl-.-pnénylalaninamide
`antiviral
`
`acetil-L-tfrosil-_-treonil--seril-L-leucil-_-isoleucil-.-histidil-L-seril-t-leucil-
`visoleucil-_-a-glutamil-.-c-glulamil-_-seril-_-giutamini-L-asparaginil-.-glutaminil-
`Uglutaminil-_-c-glutamil-_-lisi-i-asparaginii-L-e-glutamil+-glutaminil-L--glutamil-
`Lleucil-leucil-L-c-glutamil-_-leucii-.-c-asparil--lisil-t-triptofil-c-alanil-t-seril-
`L-leucil-.-triptofil-_-asparaginil-_-iriptofil--fen‘laianinamida
`antiviral
`
`105
`
`efalizumabum
`efalizumab
`
`éfaiizumab
`
`efalizumab
`
`enfuvirtidum
`enfuvirtide
`
`enfuvirtide
`
`enfuvirtida
`
`

`

`Proposed INN: List 85
`
`WHODrug Information, Voi. 15, No. 2, 2001
`
`
`
`St
`GS
`CorgcHoodNex,
`
`459519-65-0
`
`H3C.
`3 ottcher—Leu—lle—His —Ser—Lau—ile—Glu—Glu~-Ser—
`GO
`10
`Gin—Asa—GIn—Gin--Giu—Lys — Asn—Glu— Gin— Glu Leu —Leu—Glu—
`20
`Leu—Asp—lLys—Trp — Ala—Ser——Leu-—Trp~ Asn —Tip —Phe -NH
`30
`
`2-acetyl-1-alkyl-sn-glycero-3-phosphocholine deacetylase-(6-400)-peptide
`(human)
`antiallergic, antiasthmatic
`
`désacétylase-(6-400)-peptide (humaine) de la 2-acétyl-1-alkyl-sr-glycéro-
`3-phosphocholine
`antiallergique, antiasthmatique
`
`1-O-alquil-2-acetil-sn-glicera-3-fosfocolina 6-400-desacetilasa (humana)
`antialérgico, antiasmatico
`
`epafipasum
`epafipase
`
`épafipase
`
`epafipasa
`
`2018
`3107)
`"Hs 514
`
`
`CornetoragNess sae: 208576-22-1
`
`PRGNGPYSVG CTDLMFDHTN KGTFLRLYYP
`ABASFGOQTKI
`SQDNDRLDTL WIPNKEYFWG
`LSKFLGTHWL MGNILRLLFG
`SMTTPANWNS
`PLRPGEKYPL
`VVFSHGLGAF RTLYSAIGID
`
`EIGDKSWLYL
`TYYFKDQSAA
`LASHGFIVAA VEHRDRSASA
`LDIDHGKPVK
`RELKQEEETH IRNEQVRORA KECSQALSLI
`NALDLKFDME QLKDSTDREK
`IAVIGHSFGG ATVIQTLSED
`QRFRCGIALD AWMFPLGDEV YSRIPQPLFF
`INSEYFQYPA
`NIIKMKKCYS
`PDKERKMITI
`RGSVHQNFAD
`FTFATGKIIG
`
`GLHKDFDQWD
`HMLKLKGDID SNVAIDLSNK ASLAFLQKHL
`CLIEGDDENL
`IPGTNINTIN QHIMLONSSG IEKYN
`
`1-165-erythropoietin (human HMR4396), glycoferm 5
`antianaemic
`
`1-165-érythropoiétine (humaine HMR4396), glycoforme 8
`antianémique
`
`{-165-erifropoietina (humana HMR4396), glicoforma 5
`antianémico
`
`epoetinum delta
`epoetin delta
`
`époétine delta
`
`epoetina delta
`
`106
`
`

`

`WHODrug Information, Vol. 15, No. 2, 2001
`
`Proposed INN: List 85
`
`
`
`SoS AST 29
`Cgc
`aeeeNezs Osea;
`
`
`
`261356-80-3
`
` WARNEVGOQA
`
`LOLEVDKAVS
`RTEITADTFREK
`
`
`Ln
`BAEBNITTGCA __EEC SLNENI T
`SEAVLRGQAL
`ALGAQKEAIS
`GKLKLYTGEA
`
`erlosamidum
`erlosamide
`
`erlosamide
`
`erlosamida
`
`erlotinibum
`erlotinib
`
`erlotinib
`
`erlotinib
`
`* : glyccsyiationsites / sites de glycosyiation / cosicicnes ce glicosilacién
`
`(2R)-2-(acetylamino}-N-benzyl-3-methoxypropanamide
`anticonvulsant
`
`(2R)-2-(acétylamino)}-N-benzyl-3-méthoxypropanamide
`anticonvulsivant
`
`(2R)-2-(acetilamino)-N-bencil-3-mstoxipropanamida
`anticonvulsivo
`
`C,HN,O,
`
`178481-36-4
`
`N-(3-ethynylphenyl)-6, 7-bis{2-methoxyethoxy}quinazolin-4-amine
`antineoplastic
`
`N-(3-ethynylphényi)-6, 7-bis(2-méthoxyéthoxyiquinazoiin-4-amine
`antinéopiasique
`
`N-(3-etiniifeni)-6.7-bis(2-metoxietoxiiquinazolin-4-amina
`antineoplasico
`
`C.,H.N,O.
`
`183321-74-6
`
`HONUON ~
`HeeNN
`8
`“Or7“
`
`CH
`
`
`107
`
`

`

`Proposed INN: List 85
`
`WHO Drug Information, Vol. 15, No. 2, 2004
`
`
`
`2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyithiazole-5-carboxylic acid
`xanthine oxidase and xanthine dehydrogenase inhibitor
`
`acide 2-[3-cyano-4-(2-méthyipropoxy)phényl]-4-méthyithiazale-
`5-carboxylique
`inhibiteur de la xanthine oxydase et de fa xanthine déshydrogénase
`
`acide 2-[3-ciano-4-(2-metilpropoxi}fenil]-4-metiltiazol-5-carboxilico
`inhibidor de la oxidasa de xantina y la deshidrogenasa de xantina
`C,H,N,0,8
`144060-53-7
`
`CHs
`
`\
`8
`
`CO.H
`
`Ni
`
`H3C
`
`CH
`
`CN
`
`(28)-3-[2-(3,4-dimethoxyphenylethoxy]-2-[(4,6-dimethylpyrimidin-2-yl}oxy]-
`3,3-diphenylpropanoic acid
`endcthelin receptor antagonist
`
`acide (2S)-3-[2-(3,4-diméthoxyphényl)éthoxy]-2-[(4,6-dimethylpyrimidin-
`2-yl)oxy]-3,3-diphénylpropanoique
`antagoniste du récepteur de fendothéline
`
`acido (2S}-3-[2-(3,4-dimetoxifeni)etoxi]-2-[(4,6-dimetilpirimidin-2-il}oxi]-
`3.3-difenilpropancico
`antagonista del receptor de endotelina
`
`C,H,N,O,
`
`204267-33-4
`
`febuxostatum
`febuxostat
`
`febuxostat
`
`febuxostat
`
`feloprentanum
`feloprentan
`
`félaprentan
`
`feloprentan
`
`finafloxacinum
`finafloxacin
`
`finafloxacine
`
`finafloxacina
`
`108
`
`CHg
`
`“HO No
`
`
`
`oO
`
`woe DS De
`
`\ ff
`
`(-)-8-cyano-1-cyclopropyt-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3 4-b]}-
`1,4-cxazin-6(2H)}-y!)-4-oxo-1 ,4-dihydroquinoline-3-carboxyic acid
`antibacterial
`
`(-}-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-
`hexahydropyrrolo[3,4-b]-1,4-oxazin-6(24)-yl)-4-oxo-1 ,4-dihydroquinoléine-
`3-carboxylique
`antibactérien
`
`(-)-Acido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-hexahidropirrolo[3,4-]-
`1 ,4-oxazin-6(2H)-il)-4-oxo-1 ,4-dihidroquinolina-3-carboxilico
`antibacteriano
`
`

`

`WHODrug Information, Vol. 15, No, 2, 2001
`
`Proposed INN: List 85
`
`CHFN,
`NHH
`
`¢
`
`‘5
`-
`
`"
`
`N
`
`FE
`
`209342-40-5
`
`on Y
`N
`
`COnH
`
`oO
`
`gadomelitolum
`gadomelitol
`
`gadomeélitol
`
`gadomelitol
`
`hydrogen [2,2',2”,2"’-{1,4,7,10-tetraazacyclododecane-1,4,7,10-triyljtetrakis=
`(5-[[2-[[4-[[4-{[2-[[3, 5-bis(bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-
`2,4,6-tribromojcarbamoyliphenyljamino]-2-oxcelF yl]carbamoyl]phenyl]=
`carbamoyl]pheny!jamino}-2-oxcethyljamino}-5-oxopentanoato](4-)}=
`gadolinate(1-)
`diagnostic agent
`
`hydrogéno-[2,2',2".2""-[1.4,7.10-tétraazacyclododécane-1,4,7,10-triyl]tétrakis
`[5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[/2 S.38.4R.5R}-2,3,4,5,6-pentahydroxyhexyl-
`2,4.6-trisromo]carbamoyljphényllamino}-2-oxoéthyl]carbamoyl]phény|j=
`carbamoayl]phény!jamina]-2-oxoéthyljamino}-5-oxopentangato](4-)J=
`gadolinate(1-)
`produit 4 usage diagnostique
`
`hidrégeno-[2,2',2",2'"-[1,4,7, 10-tetraazaciclododecano-1,4,7,10-trilltetrakis=
`(5-[[2-[[4-[[4-([2-[[3, 5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahidroxihexil-
`2,4,6-tribromo]carbamoil]feniljamina]-2-oxoetiljcarbamoil]feniljJcarbamoilifenij=
`amino]-2-oxoetillamino]-5-oxopenianoato](4-)}gadolinato(1 -)}
`agente de diagndstico
`
`CossHers Br.,GIN.0.5
`
`oO
`
`HN
`
`HaC.~~
`
`i
`
`N
`
`R
`A
`[ NaS)
`St ou
`oAprcos
`t
`an
`A“oO
`C
`Howy\_/")003
`R
`R
`Ke
`
`oO.
`“
`
`6
`
`OH
`
`OH
`
`NH
`
`CH
`
`OH
`
`
`109
`
`

`

`Proposed INN: List 85
`
`WHODrugInformation, Vol. 15, No. 2, 2004
`
`garnocestimum
`garnocestim
`
`garnocestim
`
`garnocestim
`
`gefitinibum
`gefitinib
`
`géfitinid
`
`gefitinib
`
`ingliforibum
`ingliforib
`
`ingliforib
`
`ingliforib
`
`5-73-macrophage inflammatory protein 20. (human gene gro2)
`immunomodulator
`
`CXC chimiokine GROB-(5-73)-peptide (GRO: protéine inflammatoire humaine
`sécrétée par les macrophages)
`immunomodulateur
`
`CXC quimickina GROB-(5-73)-péptide (GROB : proteine inflamatoria humana
`secretada por los macréfagos)
`inmunomodulador
`‘325°
`“S67
`“OF
`CyHeoNg OS,
`
`24686 1-96-1
`
`|
`TELRCQ
`CLOTLQGIHL KNIQSVKVKS
`PGPHCAQTEV
`ITATLKNGOKA
`CLNPASPMVK KITEKMLKNG
`KSN
`
`N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-
`4-yl)propoxy]quinazolin-4-amine
`antineoplastic
`
`N-(3-chloro-4-fluorophényl)-7-méthoxy-6-[3-(morpholin-
`4-yl)propoxy]quinazolin-4-amine
`antinéoplasique
`
`N-(3-cloro-4-fluarofenil)-7-metoxi-6-[3-(morfolin-4-ilpropoxijquinazatin-
`4-amina
`antineoplasico
`
`C.,,H,,CIFN,O,
`
`184475-35-2
`
`H3CO.
`
`N
`SN
`coo =
`
`oJ
`
`“TOOF
`
`5-chloro-N-((1S,2R)-1 -benzyl-3-(cis-3,4-dihydroxypyrrolidin-1-yl)-
`2-hydroxy-3-oxopropyl]-1H-indole-2-carboxamide
`antidiabetic
`
`5-chlore-N-[(1 S,2R)-1 -benzyi-3-(cis-3,4-dihydroxypyrralidin-1-y!)-
`2-hydroxy-3-axopropyl]-1H-indole-2-carboxamide
`antidjabétique
`
`:
`
`5-clora-N-[(1S,2R)-4-bencil-3-(cis-3,4-dihidroxipirrolidin-1-il}-2-hidroxi-
`3-oxopropil]-1H-indol-2-carboxamida
`antidiabético
`
`
`110
`
`

`

`WHODrug Information, Vol. 15, No. 2, 2001
`
`Proposed INN: List 85
`
`ipravacainum
`ipravacaine
`
`ipravacaine
`
`ipravacaina
`
`isegananum
`iseganan
`
`iséganan
`
`iseganan
`
`CagH,.CIN.O,
`
`186392-65-4
`
`
`
`(2RS)-1-(cyclopropyimethyl)-2',6'-dimethyl-2-piperidinecarboxanilide
`local anaesthetic
`
`(2RS)-1-(cyclopropylm éthyl)-N-(2,6-diméthylphény!)pipéridine-2-carboxamide
`anesthésique local
`
`(2RS)-1-(ciclopropilmetil)-N-(2,6-dimetilfenil}piperidina-2-carboxamida
`anestésico focal
`
`
`
`C_,HN,O8 2 2
`
`166181-63-14
`
`May
`
`H.,
`
`N
`
`Oo
`CHs
`
`and enantiomer
`et énantiomeére
`y enanti6mero
`
`L-arginylglycylglycy|-t-leucyl-1-cysteinyl-tyrosyl-t-cysteinyl-t-arginylglycyl-
`L-arginyl-:-phenylalanyl-.-cysteinyl-t-valyl-L-cysteiny-1-valyiglycyl-
`L-argininamide cyclic (§14).(7->12)-bis(disulfide)
`antibacterial
`
`(5 14),(7-12)-bis(disulfure cyclique} de c-arginyl-glycyi-giycyl-t-leucy!-
`L-cysteinyl-_-tyrosyl-_-cystéiny-L-arginyl-glycyl-L-arginyl-_-phénylalanyl-
`L-cystéinyl-_-valyl-_-cystéinyl--valyl-glycy-_argininamide
`antibactérien
`
`(5-314),(712)-bis(disulfuro cictico) de L-arginil-glicil-glicil-.-leucil-.-cisteinil-
`L-tirosil-i-cisteinil-L-arginil-glicl-_-arginil-_-fenilalanil-L-cisteinil-L-valil-_-cisteinil-
`t-vaiil-glicil-.-argininamida
`antidacteriano
`
`114
`
`

`

`Proposed INN: List 85
`
`WHO Drug Information, Vol. 15, No. 2, 2001
`
`
`
`73)
`126"
`CogHyac NgaOyySq
`
`257277-05-7
`
`H-Arg— Gly —Gly—Leu—Cys —Tyr —Cys —Arg— Gly —Arg—Phe-—Cys—
`|
`
`Val—Cys —Val-—-Gly—Arg—NH»
`
`immunoglobulin G, anti-human carcinoembryonic antigen) (human-mouse
`monoclonal hMN-14 y-chain), disulfide with human-mouse monocicnal
`hMN-14 «-chain, dimer
`immunomodulator
`
`immunoglobuline G, anti-(antigene carcinoembryonnaire humain) (chaine-y de
`fanticorps monoclonal de souris humanisé hMN-14), dimére du disulfure avec
`la chaine-x de l'anticorps monoclonal de souris humanisé hMN-14
`immunomodulateur
`
`inmunoglobulina G, anti-(antigeno carcinoembrionario humano) (cadena-y del
`anticuerpo monoclonal humanizado de raton hMN-14), dimero del disulfuro
`con la cadena-« dei anticuerpo monoclonal humanizado de ratén hMN-14
`inmunomodulador
`
`219649-07-7
`
`methyl 6,1 1-dihydro-11-[1-[2-{4-(-2-quinolyimethoxy)phenyljethyl]-
`4-piperidinylidene]-5H-imidazo[2, 1-b][3]benzazepine-3-carboxylate
`antineoplastic
`
`11-[1-[2-[4-(quinoléin-2-ylméthoxy)phény|]éthy|Jpipéridin-4-ylidéne]-
`6,11-dihydro-5H-imidazo[2. 1-6][3]benzazépine-3-carboxylate de méthyle
`antinéoplasique
`
`11-[1-[2-[4-(quinolin-2-ilmetoxi}feniljetiljpiperidin-4-ilideno]-6,1 1~dihidro-
`§H-imidazo[2, 1-b][3}benzazepina-3-carboxilato de metilo
`antineoplasico
`
`labetuzumabum
`labetuzumab
`
`Jabétuzumab
`
`labetuzumab
`
`laniquidarum
`laniquidar
`
`laniquidar
`
`laniquidar
`
`112
`
`

`

`WHODrug Information, Vol. 15, No. 2, 2004
`
`Proposed INN: List 85
`
`
`
`C.,H.N,O,
`
`197509-46-9
`
`oO.
`
`N
`
`|
`
`Oo
`
`Ss
`
`N
`
`N-[1-(4-methoxypheny!)-1-methylethyl]-3-cxo-4-aza-5o-androst-1-ene-
`17B-carboxamide
`54-reductase inhibitor
`
`3-(1-benzylpipéridin-4-yl)-1-(2,3,4,5-tétrahydro-1 H-1-benzazépin-
`8-yl)propan-1-one
`inhibiteur de la 5a-réductase
`
`3-(1-bencilpiperidin-4-i!)-1-(2,3,4,5-tetrahidro-1 H-1-benzazepin-8-il)propan-
`j-ona
`inhibidor de la Sd-reductasa
`
`‘ag
`Sa)
`CH,NO,
`
`142139-60-4
`
`OCH:
`
`5-chloro-A-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-
`3-carboxamide
`immunomodutator
`
`§-chloro-N-éthyl-4-hydroxy-1 -méthyl-2-oxe-N-phényl-4,2-dihydroquinoléine-
`3-carboxamide
`immunomodulateur
`
`5-cloro-N-etil-4-hidroxi-1-metil-2-oxo-N-fenil-1 ,2-cihidroquinolina-
`3-carboxamida
`inmunomodulador
`
`lapisteridum
`lapisteride
`
`lapistéride
`
`lapisterida
`
`laquinimodum
`laquinimod
`
`laquinimod
`
`laquinimod
`
`
`113
`
`

`

`Proposed INN: List 85
`
`WHODrug Information, Vol. 15, No. 2, 2001
`
`C,,H,,CINO,
`
`248281-84-7
`
`CHy
`
`ZA
`
`OH
`
`Ci
`
`N
`
`0 O
`
`8-i-histidine-a-t-iduronidase (human)
`enzyme
`
`[8-L-histidine]-a-t-iduronidase humaine
`enzyme
`
`8-L-histidina-a-t-iduronidasa (humano)
`enzima
`
`SEO"
`(4A “gOt
`BBA
`12
`CoyercatteasaNes: Oar
`
`210589-09-6
`
`lJaronidasum
`laronidase
`
`laronidase
`
`laronidasa
`
`AEAPHLVHVD AARALWPLRR
`LSWDQQLNLA
`YVGAVPHRGI
`
`FWRSTGECPP
`KQVRTHWLLE
`
`LPHSQADOYV
`LVTTRGSTGR
`
`LLPGFELMGS ASGHFTDFED
`GLSYNFTHLD GYLDLLRENQ
`KQQVFEWKDL VSSLARRYIG RYGLAHVSKW NFETWNEPDH
`HDFDNVSMTM QGFLNYYDAC| SEGURAASPA
`LRLGGPGDSF
`HTPPRSPLSW GLLRHCHDGT NPFTGEAGVR
`LDYISLHRKG
`ARSSISILEQ EKVVAQQIRO
`LFPKFADTPI
`YNDEADPLVG
`
`VTYAAMVVKV
`WSLPQPWRAD
`LSNDNAFLSY HPEPFAQRTL
`VLTAMGLLAL
`LDEEQLWAEV
`RPQGPADAWR AAVLIYASDD
`
`IAQHONLLLA NTTSAFPYAL
`TARFOVNNTR
`PPHVQLLRKP
`SQAGTVLDSN HTVGVLASAH
`TRAHPNRSVA VTLRLRGVPP
`
`PTAEQFRRMR
`EWRRLGRPVF
`LDNGLESPDS
`GPGLVYVTRY
`LLVHVEARPE
`LRPALRLPSL
`RPLPAGGRLT
`AAEDPVAAAP
`LVWSDEHVGS KCLWIYEIOP
`KPPGQVTRLR ALPLTQGOLV
`SQDGKAYTPVY
`SRKPSTFNLF VFSPDTGAVS
`GSYRVRALDY
`WARPGPFSDP VPYLEVPVPR GPPSPGNP
`
`*: glycosylationsites / sites de glycosylation / posiciones deglicosilacién
`Lw : disulfide / disuifure / disulfuro
`
`
`114
`
`

`

`WHODrugInformation, Vol. 15, No. 2, 2001
`
`Proposed INN: List 85
`
`lirimilastum
`lirimilast
`
`lirimilast
`
`lirimilast
`
`2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfenate
`antiasthmatic
`
`méthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uréidobenzofuran-6-yle
`antiasthmatique
`
`metanesulfonato de 2-{2,4-diclorabenzoil)-3-ureidobenzofuran-6-ilo
`antiasmatico
`
`livaraparinum calcium
`livaraparin calcium
`
`livaraparine calcique
`
`livaraparina cAlcica
`
`C,;H.,CLN,O.S
`
`
`
`calcium salt of a low molecular mass heparin that is obtained by nitrous acid
`depolymerization of heparin from porcine irtestinal mucosa; the majority of
`the components have a 2-O-sulfo-c-L-idopyranosuronic acid structure at the
`non-reducing end and a 6-O-sulfc-structure at the reducing end of their
`chain; the mass-average molecular mass ranges between 3000 and 5000
`with 75% is less than 8000; the degree of sulfatation is approximately 2 per
`disaccharidic unit
`anticoagulant
`
`sel caicique d'une héparine de basse masse moléculaire obtenue par
`dépolymérisation, au moyen d’acide nitreux, d’héparine de muqueuse
`intestinale de pore ;
`la majorité des composants de ja livaraparine calcique
`possédent une structure acide 2-O-sulfo-d-L-idopyranosuronique a
`lextrémité non réductrice de leur chaine et une structure 6-O-sulfatée a
`Pextrémité réductrice de leur chaine ; la masse moléculaire relative moyenne
`est de 3000 a 5000, 75% étant inférieur 4 8000 ; le degré de sulfatation par
`unité disaccharide est voisin de 2
`anticoagulant
`
`sal calcica de una heparina de baja masa molecular cbtenida de heparina de
`mucosa intestinal de cerdo por despolimerizacién con Acido nitroso: la
`mayoria de los componentes de la livaraparina calcica tienen acida 2-O-
`sufo-a-.-idopiranosurénico en el extremo no reductor de la cadena y una
`estructura 6-O-sulfatada en el extremo reductor de la cadena: la masa
`molecuiarrelativa me dia es de 3000 a 5000, siendo el 75%inferior a 800C: el
`grado de sulfatacion por unidad de disacarido es aproximadamente 2
`anticoagulante
`
`115
`
`

`

`Proposed INN: List 85
`
`WHO DrugInformation, Vol. 15, No. 2, 2001
`
`
`
`